Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H65N5O8 |
InChIKeyMFRNYXJJRJQHNW-DEMKXPNLSA-N |
CAS Registry745017-94-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | IT | 20 Apr 2023 |